ALKS - Alkermes plc.

QQQ $ 603.51 $ -1.70 (-0.28 %)

DIA $ 462.66 $ -0.71 (-0.15 %)

SPY $ 664.69 $ -2.15 (-0.32 %)

TLT $ 90.88 $ 0.38 (0.42 %)

GLD $ 392.86 $ 1.68 (0.43 %)

Previous Close

$ 32.23

Open

$ 32.16

Bid

$ 31.42 x 101

Ask

$ 31.46 x 106

Day's Range

$ 31.47 - $ 32.26

52 Week Range

$ 25.17 - $ 36.45

Volume

1,315,923

Average Volume

Market Cap

5.32B

Beta (5Y Monthly)

$ 0.48

PE Ratio (TTM)

$ 15.17

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-29-2025	06-30-2025	10-Q
2	05-01-2025	03-31-2025	10-Q
3	02-12-2025	12-31-2024	10-K
4	10-24-2024	09-30-2024	10-Q
5	07-24-2024	06-30-2024	10-Q
6	05-01-2024	03-31-2024	10-Q
7	02-21-2024	12-31-2023	10-K
8	10-25-2023	09-30-2023	10-Q
9	07-26-2023	06-30-2023	10-Q
10	04-26-2023	03-31-2023	10-Q
11	02-16-2023	12-31-2022	10-K
12	11-02-2022	09-30-2022	10-Q
13	07-27-2022	06-30-2022	10-Q
14	04-27-2022	03-31-2022	10-Q
15	02-16-2022	12-31-2021	10-K
16	10-27-2021	09-30-2021	10-Q
17	07-28-2021	06-30-2021	10-Q
18	04-28-2021	03-31-2021	10-Q
19	02-11-2021	12-31-2020	10-K
20	10-29-2020	09-30-2020	10-Q
21	07-29-2020	06-30-2020	10-Q
22	04-29-2020	03-31-2020	10-Q
23	02-13-2020	12-31-2019	10-K
24	10-23-2019	09-30-2019	10-Q
25	07-25-2019	06-30-2019	10-Q
26	04-25-2019	03-31-2019	10-Q
27	02-15-2019	12-31-2018	10-K
28	10-23-2018	09-30-2018	10-Q
29	07-26-2018	06-30-2018	10-Q
30	04-26-2018	03-31-2018	10-Q
31	02-16-2018	12-31-2017	10-K
32	10-26-2017	09-30-2017	10-Q
33	07-27-2017	06-30-2017	10-Q
34	04-27-2017	03-31-2017	10-Q
35	02-17-2017	12-31-2016	10-K
36	11-02-2016	09-30-2016	10-Q
37	07-28-2016	06-30-2016	10-Q
38	04-28-2016	03-31-2016	10-Q
39	02-25-2016	12-31-2015	10-K
40	10-29-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

9 Analysts Assess Alkermes: What You Need ...
09/26/2025 13:00:29

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts...

this-ciena-analyst-turns-bullish-here-are-top-5-upgrades-for-friday

This Ciena Analyst Turns Bullish; Here Are...
09/26/2025 11:55:03

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

RBC Capital Upgrades Alkermes to Outperfor...
09/26/2025 11:40:04

RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price ...

Alkermes Appoints Joshua Reed As CFO, Effe...
09/12/2025 13:01:24

JP Morgan Maintains Neutral on Alkermes, R...
09/09/2025 19:43:27

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $34 to $35.

HC Wainwright & Co. Reiterates Neutral on ...
09/09/2025 10:48:19

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.

Alkermes Vibrance 1 Study Demonstrates Ali...
09/08/2025 07:18:30

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cog...

Deep Dive Into Alkermes Stock: Analyst Per...
09/03/2025 20:00:35

macys-increases-fy2025-outlook-joins-rev-group-healthequity-alphabet-and-wellness-and-other-big-stocks-moving-higher-on-wednesday

Macy's Increases FY2025 Outlook, Joins REV...
09/03/2025 14:10:50

this-unisys-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday

This Unisys Analyst Begins Coverage On A B...
09/03/2025 12:40:11

Wells Fargo Initiates Coverage On Alkermes...
09/03/2025 12:35:48

Wells Fargo analyst Benjamin Burnett initiates coverage on Alkermes (NASDAQ:ALKS) with a Overweight rating and announces Pri...

bruker-mineralys-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

Bruker, Mineralys Therapeutics And Other B...
09/03/2025 12:17:14

Alkermes To Present Detailed Results From ...
08/25/2025 11:07:52

Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures,...

RBC Capital Maintains Sector Perform on Al...
07/30/2025 13:56:51

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Sector Perform and raises the price target from ...

Needham Reiterates Buy on Alkermes, Mainta...
07/29/2025 12:03:26

Needham analyst Ami Fadia reiterates Alkermes (NASDAQ:ALKS) with a Buy and maintains $45 price target.

Alkermes Affirms FY2025 GAAP EPS Guidance ...
07/29/2025 11:06:29

Alkermes (NASDAQ:ALKS) affirms FY2025 GAAP EPS guidance from $1.03-$1.21 to $1.03-$1.21 vs $1.15 analyst estimate. Affirms FY20...

Alkermes Q2 EPS $0.52 Beats $0.24 Estimate...
07/29/2025 11:03:58

Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.24 by 117...

Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

alkermes-oral-drug-helps-patients-stay-awake-in-mid-stage-sleep-disorder-study

Alkermes Oral Drug Helps Patients Stay Awa...
07/21/2025 17:29:02

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

HC Wainwright & Co. Reiterates Neutral on ...
07/21/2025 16:11:29

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.